ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,300.33
-0.14%
Dow Jones
43,828.06
-0.20%
Gold vs US Dollar
2,648.955
0.00%
Brent Oil
74.135
0.00%
Bitcoin
101,759.16
0.30%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Innate Pharma SA (IPHA) Share Price

IPHA Innate Pharma SA

3.00
1.45 (93.55%)
14 Dec 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Innate Pharma SA NASDAQ:IPHA NASDAQ Depository Receipt  Sponsored ADS France
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   1.45 93.55 3.00 2.89 3.05 3.5107 1.47 1.5 13,593,143 01:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 61.64M -7.57M -0.0941 -20.19 124.7M
 Type  Size  Price  Time  Units 
 9 10 3.00 00:59:18 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore IPHA News
09/12/202411:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
09/12/202406:00BWInnate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanés
09/12/202406:00BWInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
06/12/202411:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
06/12/202406:00BWInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
06/12/202406:00BWInnate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaire
03/12/202411:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Period
Draw mode
Data Downloads for IPHA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Innate Pharma SA Articles